CER 001
Alternative Names: CER-001; Cerenis HDL; Recombinant Human Apolipoprotein A-I; Recombinant Human Apolipoprotein A-I/Phospholipids complexLatest Information Update: 17 Jun 2024
At a glance
- Originator Cerenis Therapeutics
- Developer ABIONYX Pharma; Academic Medical Center
- Class Antihyperlipidaemics; Apolipoprotein therapeutics; Cardiovascular therapies; Eye disorder therapies; Phospholipids; Recombinant proteins; Vascular disorder therapies
- Mechanism of Action Apolipoprotein A-I replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypoalphalipoproteinaemia
- Phase II Acute coronary syndromes; Acute kidney injury; Atherosclerosis
- Clinical Phase Unknown COVID 2019 infections; Lecithin acyltransferase deficiency
- Preclinical Uveitis
- No development reported Lipid metabolism disorders
Most Recent Events
- 13 Jun 2024 ABIONYX Pharma completes a pre-IND meeting with the US FDA and receives feedback to support an IND filing of CER 001 for sepsis-induced Acute kidney injury
- 13 Jun 2024 ABIONYX Pharma plans to file an IND application for sepsis-induced Acute kidney injury
- 13 Jun 2024 ABIONYX Pharma plans a phase IIb/III trial for sepsis-induced Acute kidney injury